ClinicalTrials.gg
CompletedNCT04382885Updated Apr 12, 2022

Cariprazine Pediatric ASD PK Study

A Phase 1 interventional study of Cariprazine in Autism Spectrum Disorder, sponsored by AbbVie. Completed at 3 sites in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-04-12.

Primary conditionAutistic DisorderRegistry: Autism Spectrum DisorderReclassifiedWhy we changed it
Registry
Autism Spectrum Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Autistic Disorder
Why
  1. The study's listed conditions name Autistic Disorder, a narrower term within Autism Spectrum Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 603 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.

Enrollment
358th of 504
24 · median 44
Started
2020
with 16 others
Phase 1
42 of 603
7 open now
Registered
389th of 603
by date

Among the 603 studies in Autistic Disorder with a site in United States, this one is the 358th largest by enrollment of the 504 interventional ones that give a count, is one of 17 that started in 2020, is one of 42 in phase 1, and was the 389th registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

123 of the 603 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Autistic Disorder with a site in United States, or all of them as a file.
02

Study summary

This study will be a multi-center, open-label, parallel-group, multiple-dose study in up to 24 male and female participants aged 5 through 17 years, inclusive, with Autism Spectrum Disorder (ASD). The 24 participants will be enrolled into 1 of 4 cohorts (6 participants per cohort).

03

Conditions studied

  • Autism Spectrum Disorder

Browse trials for

Keywords

  • ASD
  • Autism
04

In context

Autistic Disorder Reclassified

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

This study's enrollment of 24 is below the median of 49 across 813 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet the (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) criteria for ASD (Autism Spectrum Disorder) diagnosis.
  • Participants must have normal physical examination findings and clinical laboratory test results for their age group or abnormal results judged not by the investigator.
  • Negative serum hCG (human chorionic gonadotropin) pregnancy test at screening (all female participants that have reached menarche).
  • greater than the 5th percentile for age and gender based on CDC (Centers for Disease Control and Prevention) growth charts.
  • Participant (if reached his spermarche or her menarche), must agree to sexual abstinence or to use an approved method for the full duration of participation in the study. The investigator and each participant will determine the appropriate method of contraception for the participant during their participation in the study.
  • Participant's parent(s)/legal representative(s) must be capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICF and in the protocol as explained by the investigator. Written informed consent from the participant's parent(s)/legal representative(s) must be obtained prior to any study-related procedures.
  • Assent (unless local regulations require consent) must be obtained for all participants participating in the study.
  • Participant must have a parent or legal representative who is willing and able to be responsible for safety monitoring of the participant, provide information about the participant's condition, oversee administration of study intervention, and accompany the participant to all study visits. The caregiver can be the participant's parent(s)/legal representative(s). Written consent from the caregiver must be obtained.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder due to another medical condition.
  • Diagnosis of intellectual disability (IQ \< 70) documented by school record, neuropsychological testing or medical records.
  • Participant has a history of meeting diagnosis for any substance-related disorder (except caffeine- and tobacco-related) within the 3 months before the Screening Visit.
  • Participant with an acute or unstable medical condition, including (but not limited to) inadequately controlled diabetes, hepatic insufficiency (specifically any degree of jaundice), uncorrected hyper- or hypo-thyroidism, acute systemic infection, renal, gastrointestinal, respiratory, or cardiovascular disease.
  • History of seizures, with the exception of febrile seizures.
  • History of tumor of the central nervous system.
  • Previously taken cariprazine or previously participated in an study of cariprazine.
  • Participant is currently enrolled in an investigational drug or device study or participation in such a study within 3 months of Study Day 1.
  • Participation in a blood or plasma donation program within 60 or 30 days, respectively, prior to Study Day 1.
  • Positive UDS for substances of abuse at the Screening Visit or on Study Day -1.
  • Known allergy or sensitivity to the study intervention or its components.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1 (10-17 years)

    10 to 12 years: 0.75 mg/day cariprazine oral solution 13 to 17 years: 1.5 mg/day cariprazine oral solution

    Drug: Cariprazine

  • Experimental
    Cohort 2 (10-17 years)

    10 to 12 years: 1.5 mg/day cariprazine oral solution 13 to 17 years: 3.0 mg/day cariprazine oral solution

    Drug: Cariprazine

  • Experimental
    Cohort 3 (5-9 years)

    0.5 mg/day cariprazine oral solution

    Drug: Cariprazine

  • Experimental
    Cohort 4 (5-9 years)

    1.5 mg/day cariprazine oral solution

    Drug: Cariprazine

Interventions

07

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: Up to 30 days after last visit or last dose for participants who discontinue early

  2. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 30 days after last visit or last dose for participants who discontinue early

  3. Incidence of AEs leading to discontinuation

    Time frame: Up to 30 days after last visit or last dose for participants who discontinue early

  4. Percentage of participants with potentially clinically significant values in clinical laboratory assessments

    Time frame: Up to 84 days

  5. Percentage of participants with potentially clinically significant values in vital signs assessments

    Time frame: Up to 84 days

  6. Percentage of participants with potentially clinically significant values in ECG assessments

    Time frame: Up to 84 Days

  7. Percentage of participants who have suicidal ideation or suicidal behaviors in C-SSRS assessments

    Time frame: Up to 84 Days

  8. Percentage of participants with treatment-emergent parkinsonism in SAS assessments

    Time frame: Up to 84 Days

  9. Percentage of participants with treatment-emergent akathisia in BARS assessments

    Time frame: Up to 84 days

  10. Percentage of participants with potentially clinically significant values in ocular examination parameters

    Time frame: Screening to Day 84

  11. Pharmacokinetics: Maximum plasma concentrations (Cmax) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42

    Time frame: Day 1 and Day 42

  12. Pharmacokinetics: Time of maximum plasma concentrations (Tmax) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42

    Time frame: Day 1 and Day 42

  13. Pharmacokinetics: Area under the plasma concentration-time curve during the dosing interval (AUC0-tau) of cariprazine and its metabolites DCAR and DDCAR on Days 1 and 42

    Time frame: Day 1 and Day 42

  14. Pharmacokinetics: Terminal elimination half-life (T1/2) of cariprazine and its metabolites DCAR and DDCAR

    Time frame: Day 42 to Day 84

  15. Pharmacokinetics: Minimum plasma concentrations (Cmin) during the dosing interval of cariprazine and its metabolites DCAR and DDCAR on Day 42

    Time frame: Day 42

  16. Pharmacokinetics: Average plasma concentrations (Cavg) during the dosing interval of cariprazine and its metabolites DCAR and DDCAR on Day 42

    Time frame: Day 42

  17. Pharmacokinetics: Apparent total clearance of cariprazine from plasma (CL/F) on Day 42

    Time frame: Day 42

  18. Pharmacokinetics: Volume of distribution during the terminal elimination phase (Vz/F) of cariprazine

    Time frame: Day 42 to Day 84

08

Study locations

3 sites
  • Neuropsychiatric Research Center of Orange County /ID# 233663
    Orange, California 92868, United States
  • Atlanta Center for Medical Research /ID# 233576
    Atlanta, Georgia 30331, United States
  • iResearch Atlanta, LLC /ID# 233614
    Decatur, Georgia 30030, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Dec 2021, 17 months.

Of 19 phase 1 interventional studies under Autistic Disorder, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2020
First posted
May 11, 2020
StartActual
Jun 26, 2020
Primary completionActual
Dec 10, 2021
CompletionActual
Dec 10, 2021
Last update
Apr 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04382885
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 11, 2020
Start date
Jun 26, 2020
Primary completion
Dec 10, 2021
Completion
Dec 10, 2021
Last update
Apr 12, 2022

Study contacts

ALLERGAN INC.
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion